Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies 2024 Global Healthcare Conference June 5, 2024 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Michael Yee I am very happy to have up here with us Chief Medical Officer of Gilead, Merdad Parsey. It's great to have you with us fresh off of four or five days of ASCO. So lots to talk about. Question-and-Answer Session Q - Michael Yee Maybe just opening up for Gilead, I'd love to just have y ...

Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies 2024 Global Healthcare Conference June 5, 2024 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Michael Yee I am very happy to have up here with us Chief Medical Officer of Gilead, Merdad Parsey. It's great to have you with us fresh off of four or five days of ASCO. So lots to talk about. Question-and-Answer Session Q - Michael Yee Maybe just opening up for Gilead, I'd love to just have y ...

Gilead Sciences, Inc. (GILD) and partner Arcus Biosciences, Inc. (RCUS) announce new data from Cohort B of the ARC-9 study.ARC-9 is a phase Ib/II study evaluating the safety and efficacy of etrumadenant (E), a dual A2a/A2b adenosine receptor antagonist, plus anti-PD-1 antibody zimberelimab (Z), FOLFOX and bevacizumab (“EZFB”), in three cohorts of patients suffering from metastatic colorectal cancer (mCRC).Cohort B of ARC-9 randomized 112 patients with comparable baseline characteristics between two arms: EZ ...

ffikretow/iStock via Getty Images My last article about Gilead Sciences, Inc. (NASDAQ:GILD) was published in August 2023 and once again the stock declined while the overall market outperformed. Back then, the stock was trading for $77, and Gilead Sciences declined 12% while the S&P 500 (SPY) increased 20% in the same timeframe. But the story that Gilead Sciences underperformed the S&P 500 is not news at this point. Gilead Sciences underperformed the S&P 500 basically on every timeframe - 6 months, 1 year, 3 ...

Olivier Le Moal I will say this pick is based more on a hunch (honed over 37 years of trading) than any concrete news catalyst or technical trading evidence. I bought a stake in Gilead Sciences (NASDAQ:GILD) recently on the view a bear market and recession will eventually force investors to move money into defensive ideas like pharmaceuticals. This group has an excellent history of witnessing massive flight-to-safety money flows during stressful periods overall on Wall Street. Specifically, Gilead has p ...

Yuji SakaiMy goal is to track the 500 world's best companies, and we use a few lists as a proxy. Every dividend aristocrat and champion, including foreign ones (25-plus year dividend growth streaks). Top 100 holdings in VIG (aristocrat and future aristocrat ETF). Top 100 holdings in SCHD (gold standard high-yield blue-chip ETF). Top 100 holdings in IWY (gold standard growth ETF). A recent addition is Gilead Sciences (NASDAQ:GILD), which many people have asked me about recently, as the yield has risen ...

While it tends to fly under the radar for many people, the biotech industry has seen a resurgence in investor interest over the last couple of years. While there could be several reasons for this, such as the COVID-19 pandemic bringing the value of biotechnology to the forefront or even the expansion of education in the biosciences, the fact remains – biotech is getting more attention than ever before. Nowadays, both institutional and retail investors are discussing which are the best biotech stocks to buy ...

Gilead Sciences, Inc. (GILD) announced positive interim results from the ongoing ASSURE study on pipeline candidate seladelpar. ASSURE is an open-label study evaluating the long-term safety and efficacy of seladelpar, a once-daily potent and selective peroxisome proliferator-activated receptor (PPAR) delta agonist or delpar. Seladelpar is a first-in-class oral, selective PPAR-delta agonist or delpar is being evaluated for treating primary biliary cholangitis (PBC). The study enrolled adult patients with PBC ...

Summary of Gilead Sciences, Inc. Conference Call Company Overview - **Company**: Gilead Sciences, Inc. (NASDAQ:GILD) - **Event**: RBC Capital Markets Global Healthcare Conference - **Date**: May 15, 2024 - **Participants**: Johanna Mercier (Chief Commercial Officer), Brian Abrahams (Senior Biotech Analyst at RBC Capital Markets) Key Points on HIV Franchise - **Market Leadership**: Gilead holds over 70% market share in the HIV treatment market, primarily driven by Biktarvy, which has a 49% share in the daily oral segment [3][4] - **Market Growth**: The HIV treatment market grows annually by 2-3%, with Gilead's Biktarvy showing a 3% year-on-year market share growth in Q1 [3][4] - **Long-Acting Treatments**: Gilead is developing long-acting oral treatments and injectables, including lenacapavir, which is expected to enhance adherence and drive growth [4][5][6] - **Prevention Market**: The HIV prevention market is currently about $3 billion, with Gilead holding over 40% share through Descovy. The market is growing at approximately 11% year-on-year [7][9] - **Future Opportunities**: Lenacapavir for PrEP (pre-exposure prophylaxis) is anticipated to launch by late 2025, potentially doubling the market size due to its less frequent dosing [8][9][10] Financial Guidance - **2025 Outlook**: Gilead expects flat growth for HIV in 2025 due to the impact of the IRA (Inflation Reduction Act) but anticipates a reset to growth in 2026 [12][13] Oncology Insights - **Trodelvy Performance**: Trodelvy is the leading treatment for second-line metastatic triple-negative breast cancer, with significant room for growth as only 1/3 of eligible patients are currently treated with it [15][16] - **Bladder Cancer**: Gilead has conditional approval for bladder cancer treatment and is awaiting data from the TROPiCS-04 trial, which could establish a stronger position in the second-line setting [16][17] - **Lung Cancer**: Gilead is exploring opportunities in lung cancer, with ongoing trials and data expected to be presented at ASCO [18][19] New Product Development - **Seladelpar for PBC**: Gilead is preparing to launch Seladelpar for primary biliary cholangitis (PBC) in Q3 2024, targeting a market of approximately 130,000 patients in the U.S. [22][24] - **Multiple Myeloma**: Gilead is collaborating with Arcellx to develop Anito-cel for multiple myeloma, with a market opportunity estimated at $12 billion [27][28] Strategic Focus - **Therapeutic Areas**: Gilead is focusing on urology, inflammation, and oncology for future growth and potential acquisitions [36][38] - **Pipeline Confidence**: The company expresses strong confidence in its current pipeline and growth opportunities over the next 5 to 10 years [39] Additional Insights - **Market Dynamics**: The HIV prevention market is expected to expand significantly with new entrants, increasing awareness and treatment uptake [7][10] - **Patient Demographics**: Current PrEP treatments primarily serve affluent demographics, indicating a need for broader outreach to underserved populations [9][10] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Gilead's market position, growth opportunities, and future product developments.

Gilead Sciences, Inc. (NASDAQ:GILD) BofA Securities 2024 Health Care Conference May 14, 2024 2:20 PM ET Company Participants Geoff Meacham - Bank of America Securities Conference Call Participants Andrew Dickinson - Chief Financial Officer Geoff Meacham For the first day of the BofA Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. We're thrilled today to have Gilead Sciences. And with me on stage is CFO, Andy Dickinson. Andy, good to see you. Andrew Dickinson Thank yo ...